Reduction or withdrawal of etanercept after remission with etanerceptin patients with rheumatoid arthritis patients.

Reduction or withdrawal of etanercept after remission with etanerceptin patients with rheumatoid arthritis patients. - Reduction of etanercept after remission in RA patients.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012613

Enrollment

Registered

2013-12-20

Start date

2012-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid arthritis

Interventions

etanercept50mg/wk or25mg twice/wk reduction of etanercept to 25mg/wk arfter 3 months from remission

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients within remission stage(DAS28 under 2.6) after etanercept50mg/wk or25mg twice/wk

Exclusion criteria

Exclusion criteria: patients withoout remission stage(DAS28 under 2.6) after etanercept50mg/wk or25mg twice/wk

Design outcomes

Primary

Measure	Time frame
activity score of rheumatoid arthritis: DAS(Disease Activity Score),swollen joint count, tender joint cont, ESR, patient VAS, CRP	—

Countries

Japan

Contacts

Public ContactMikio Nakajima

Osaka Medical College Dept. of orthopedic surgery

ort054@poh.osaka-med.ac.jp072-683-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026